Dyslipidemias
Conditions
Keywords
Functional food, Common bean, Snack
Brief summary
Introduction: The Mexican population consumes vegetables and snacks with the same frequency. Besides, most of the snacks available on the market contain high fat, sodium and calorie, and low protein levels. Regular consumption of these snacks and low physical activity could promote the development of noncommunicable diseases. Common bean-based snacks are potential healthier alternatives to replace conventional snacks. Hypothesis: The consumption of a common bean baked snack (Phaseolus vulgaris L.) reduces blood lipid levels in overweight people with altered blood lipid levels. Objectives: Evaluate the effect of common bean baked snack consumption on blood lipid levels in overweight people with altered blood lipid levels. Material and Methods: Randomized crossover clinical trial, 28 patients with altered blood lipid levels, 18-40 years old, snack supplementation for four weeks, clinical and laboratory determinations, such as total cholesterol, triglycerides, LDL, HDL, among others. * Intervention phase: Common bean baked snack intervention. * Control phase B: No intervention.
Interventions
OTHERSnack
Participants will consume 32 g of a common bean baked snack per day for 28 days during the intervention stage.
Sponsors
Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco
Centro Universitario de Ciencias de la Salud, Mexico
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
* BMI between 25.0 and 29.9 kg/m2, * Abnormal serum lipid levels: * Total cholesterol: ≥200 mg/dL, * Low-density lipoproteins: 100 to 190 mg/dL, * High-density lipoproteins: \<50 mg/dL in females and \<40 mg/dL in males, * Triglycerides: 150 to 500 mg/dL.
Exclusion criteria
* Pregnancy or lactation, * Plans to lose or gain weight in the next three months, * Modification of diet or physical activity in the last three months, * Diagnosis of diabetes, cancer, hypertension, heart disease, gastrointestinal disorder, pancreatitis, kidney, liver or thyroid disease, * Smoking or drug use, * Sensitivity for bean consumption, * Pharmacological treatment or consumption of non-prescription drugs, herbal or nutritional supplements known to modify serum lipid levels.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in the mean low-density lipoprotein (mg/dL) at 28 days | Baseline and 28 days |
| Change from baseline in the mean high-density lipoprotein (mg/dL) at 28 days | Baseline and 28 days |
| Change from baseline in the mean total cholesterol (mg/dL) at 28 days | Baseline and 28 days |
| Change from baseline in the mean triglycerides (mg/dL) at 28 days | Baseline and 28 days |
Countries
Mexico
Outcome results
None listed